Recently, Wuxi Further Pharmaceutical Co., Ltd. came with major R&D good news - the invention patent application for "a PDRN-cross-linked collagen gel and its preparation method" declared by the company was officially accepted by the China Patent Office (Application number: 202610190499. X). The landing of this patent marks a key step in the company's technological layout in the field of regenerative biomaterials, and also brings new technical solutions to medical aesthetic repairs, medical dressings and other fields.
Patent core analysis: dual-effect synergy unlocks a new dimension of regeneration and repair
The patent accepted focuses on the innovative preparation technology of PDRN-cross-linked collagen gel, which is an important breakthrough in the intersection of biomedicine and regenerative medicine. The patent document clearly shows that the invention was jointly tackled by three core R&D personnel, Tang Shiqi, Qian Yu and Wu Pengcheng, and after multiple rounds of experimental optimization, a complete technical solution was formed.
From the perspective of technical principles, this gel achieves the precise fusion and synergy of the two core biomaterials:
1. PDRN (polydeoxyribonucleotide): As the "star ingredient" in the field of regenerative medical aesthetics, PDRN is derived from biologically active DNA fragments, which has high homology with human DNA, and has the core effects of anti-inflammatory, promoting angiogenesis and accelerating cell repair.
2. Cross-Linked Collagen: Collagen is the core component of the dermis of the skin, and the introduction of cross-linking technology greatly improves the stability, biocompatibility and mechanical strength of collagen, which not only solves the pain points of ordinary collagen that is easy to degrade and insufficient support, but also provides physical support for skin tissue to achieve the dual effect of "Repair + Support".
Through an innovative preparation method, PDRN cross-linked collagen are organically combined, which not only retains the biological activity of PDRN, but also gives the gel the characteristics of long-acting sustained-release and targeted delivery, breaking through the efficacy limitations of traditional single-component repair products and filling the market gap of "high activity + strong support" compound biogels.
Technical value is highlighted: it accurately meets the rigid needs of industry upgrading
At present, the medical aesthetics and regenerative medicine industry is undergoing a core transformation from "simple filling" to "regenerative repair". Consumers' demand for skin care has been upgraded from basic hydration and moisturizing to the compound demand of anti-inflammatory repair and anti-aging regeneration. However, traditional hyaluronic acid and single collagen products are difficult to meet the dual demands of "deep repair" and "long-term support" at the same time.
According to industry research data, the global PDRN market is expanding rapidly at a compound annual growth rate of 43%, and China, as the world's largest PDRN consumer market, has long faced the dilemma of imported products dominated by imported products and insufficient domestic technology breakthroughs. At the same time, the market size of recombinant collagen raw materials has grown by more than 30% annually, but the research and development of compound gel products is still in its infancy.
Wuxi Futher Pharmaceutical's PDRN-cross-linked collagen gel patent accurately hits the pain points of industry upgrading: on the one hand, it replaces import dependence through domestic technology, reduces the cost of terminal products, and promotes industry inclusiveness; On the other hand, the innovative "dual-component synergy" technology not only meets the compliance requirements in the context of stricter supervision, but also can provide high value-added core raw materials for medical aesthetic institutions and medical dressing enterprises, and the market potential is huge.
The original intention of R&D: Empower industrial development with technological innovation
As an enterprise deeply involved in the field of medicine and biological materials, Wuxi Further Pharmaceutical has always taken "technological innovation" as its core competitiveness. The acceptance of this patent is not only the embodiment of the company's R&D team's spirit of tackling tough problems, but also an important achievement of the company's practice of "combination of production, education, research and application" and helping the autonomy of domestic biological materials.
In the future, the company will continue to deepen the research and development and application of regenerated materials such as PDRN cross-linked collagen with this patent as a starting point, and promote the transformation of technological achievements into multiple scenarios such as medical aesthetic products, medical repair products, and functional skin care products. At the same time, it will speed up the process of patent substantive examination, accelerate product implementation, provide consumers with safer, more efficient and scientific skin repair solutions, and inject new momentum into the high-quality development of regenerative medical aesthetics and biomedical industry.
This patent acceptance is an important milestone in Wuxi Further Pharmaceutical's technological innovation, and it is also a vivid practice for domestic biological material enterprises to break through technical barriers and seize industry opportunities. We look forward to the further maturity of the technology, and this innovative gel can truly enter the lives of the public, allowing more people to enjoy the health and beauty brought by regenerative medicine.
Wu Xi Further Pharmaceutical Co.,Ltd
Main Products
Palmitoylethanolamide(PEA) Micro (CAS 544-31-0)
Spermidine trihydrochloride(CAS 334-50-9)
Pterostilbene(CAS 537-42-8)
Luteolin (CAS 491-70-3)
Voglibose (CAS 83480-29-9) JP GMP
Mailbox:wuxifurther@gmail.com
Whatsapp:+86 18036885286
